Conversion to Rapamycin Immunosuppression for Malignancy After Kidney Transplantation

Transplantation Proceedings

Volumn 42, Issue 4, 2010, Pages 1314-1316

  Manuelli, M ^a   De Luca, L ^a   Iaria, G ^a   Tatangelo, P ^a   Sforza, D ^a   Perrone, L ^a   Bellini, M I ^a   Angelico, R ^a   Anselmo, A ^a   Tisone, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; BILATERAL CANCER; BILATERAL NEPHROUROTHELIOMA; BILATERLA NEPHROUROTHELIOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CHILD; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; COLON CANCER; COLON CARCINOMA; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIPOSARCOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; METASTASIS; METASTASIS POTENTIAL; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; PRIORITY JOURNAL; PROTEINURIA; SCHOOL CHILD; SKIN CANCER; SPERMATIC CORD; STOMACH CANCER; TREATMENT RESPONSE; TUMOR REGRESSION;

CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; GENITAL NEOPLASMS, MALE; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIPOSARCOMA; MALE; NEOPLASM METASTASIS; NEOPLASMS; SIROLIMUS; SKIN NEOPLASMS; STOMACH NEOPLASMS;

EID: 77952579612     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.03.051     Document Type: Article

References (9)

1. Guba M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of VEGF. Nat Med (2002)
2. Kasiste B.L., Snyder J.J., Gilbertson D.T., et al. Cancer after kidney transplantation in the United States. Am J Tranplant 4 (2004) 905
3. Yakupoglu Y.K., Buell J.F., and Kahan B.D. Individualization of immunosuppressive therapy. Tranplant Proc 38 (2006) 358
4. Kohel G.E. Rapamycin and tumor growth: mechanism behind it's a cancer activity. Transplant Rev (2005)
5. Campistol J.M., Eris J., Oberbauer R., et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 17 (2006) 581
6. Stallone G., Schena A., Infante B., et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352 (2005) 25
7. Cullis B., D'Souza R., Mc Cullagh P., et al. Sirolimus induced remission of post-transplantation linphoproliferative disorder. Am J Kidney Dis 47 (2006) 67
8. Garcia V.D., Bonamigo-Filho J.L., Neumann J., et al. Rituximab in association with rapamycin for post- transplant linphoproliferative disease treatment. Transpl Int 16 (2003) 202
9. Monaco A.P. The role of mTOR inhibitors in the management of post-transplant malignancy. Transplantation (2009)